Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Fleming AD, Palka P, McDicken WN, Fenn LN, Sutherland GR. Verification of cardiac Doppler tissue images using grey-scale M-mode images. Ultrasound Med Biol. 1996 Jan 1;22(5):573-81. doi: 10.1016/0301-5629(95)02065-9
Fleming AD, McDicken WN, Sutherland GR, Hoskins PR. Assessment of colour Doppler tissue imaging using test-phantoms. Ultrasound Med Biol. 1994 Jan 1;20(9):937-51. doi: 10.1016/0301-5629(94)90053-1